Jazz Pharmaceuticals Rides Record Q1 and Oncology Gains

Jazz Pharmaceuticals ((JAZZ)) has held its Q1 earnings call. Read on for the main highlights of the call.

Jazz Pharmaceuticals’ latest earnings call struck an overall optimistic tone, with management emphasizing record first‑quarter revenue, accelerating growth in key franchises and a strengthening oncology story. Executives acknowledged some one‑off benefits and looming competitive and policy risks, but argued that robust cash generation, pivotal trial wins and looming regulatory decisions position the company for continued momentum.

Record Q1 Revenue and Reaffirmed Growth Ambitions

Jazz reported its highest ever first‑quarter revenue, in the range of $1.07 billion to $1.10 billion, translating to more than 19% year‑over‑year growth. Non‑GAAP adjusted EPS reached $6.34, and management reiterated its full‑year 2026 revenue outlook of $4.25 billion to $4.5 billion, underscoring confidence in the durability of the current growth trajectory.

Oncology Portfolio Delivers 45% Growth Surge

The oncology franchise was a standout, expanding 45% year over year as Zepzelca and new assets drove upside. Zepzelca sales jumped 60% to $101 million, while early contributions from Midevo and ZYHERA helped build a diversified cancer revenue base and reinforced oncology as a central growth engine.

Zanidatumab Data Underscore Transformative Potential

In gastric and esophageal cancer, the Horizon GEA trial triplet arm for zanidatumab delivered a median overall survival of 26.4 months, more than six months better than prior HER2‑positive metastatic GEA benchmarks. The FDA has accepted a supplemental filing for ZYHERA with Priority Review, setting up a key regulatory decision in late August 2026.

Sleep and Epilepsy Franchises Maintain Solid Expansion

Jazz’s established sleep and epilepsy businesses continued to grow, with Xywav sales rising 18% to $408 million and the active patient base reaching about 16,600, aided by roughly 425 net additions. Epidiolex posted 15% sales growth to $250 million on 16% volume expansion, reflecting increased uptake in adult and long‑term care settings.

Midevo Launch Shows Strong Early Traction

Newly launched Midevo generated $41 million in first‑quarter revenue, with around 500 patients treated since its August 2025 debut, highlighting notable early demand. Management believes Midevo could ultimately reach a roughly $500 million peak U.S. opportunity, particularly if the ACTION trial supports use in earlier treatment lines.

Cash Generation Bolsters Balance Sheet Flexibility

The company’s financial position strengthened further as it generated $408 million of operating cash flow in the quarter, ending with $2.9 billion in cash and investments. This liquidity gives Jazz ample room to fund R&D, support launches and pursue business development while navigating market and policy uncertainty.

Pipeline Progress and Near‑Term Catalysts

Beyond ZYHERA in GEA, Jazz highlighted multiple zanidatumab programs, including a post‑ENHERTU breast cancer study and several registrational and early‑stage trials. Interim overall survival readouts from ACTION are anticipated in late 2026 or early 2027, and additional data are slated for presentation at ASCO, offering a steady stream of potential catalysts.

Incoming Competition in the Oxybate and Sleep Arena

Management cautioned that the oxybate and broader sleep market will face intensifying competition in the second half of 2026, including rising high‑sodium generics and possible new daytime wake‑promoting agents. They anticipate declines in Xyrem and high‑sodium authorized generic revenues as lower‑priced products gain share.

Impact of One‑Off and External Tailwinds on Growth

The finance team noted that headline growth benefited from a 13‑week shipping quarter versus 12 weeks a year ago, which added roughly two percentage points to revenue growth. Foreign exchange provided another roughly 1.5‑point boost, signaling that a portion of the reported acceleration reflects timing and FX rather than purely underlying demand.

Gross Margin Pressure from Royalty‑Bearing Mix

Non‑GAAP adjusted gross margin edged down slightly year over year, driven mainly by a higher mix of royalty‑bearing products such as Zepzelca and Midevo. While these therapies are key growth drivers, their economics weigh on margins, and management signaled ongoing attention to balancing portfolio mix and profitability.

Litigation and Market‑Access Risks Temper Outlook

Jazz is engaged in ongoing ANDA litigation related to Zepzelca and other intellectual‑property matters, creating some uncertainty around exclusivity timelines. The company is also mindful of evolving international pricing discussions, including reference pricing, which could influence the ex‑U.S. strategy for ZYHERA and other pipeline assets.

Rising Operating Investment Supports Pipeline and Launches

On the cost side, non‑GAAP SG&A fell about $164 million due to a large litigation settlement in the prior‑year quarter, but excluding that effect it actually increased by roughly $8 million, reflecting higher commercial spend. Non‑GAAP R&D rose about $13 million, driven by Midevo trial costs and higher compensation, signaling continued investment behind the pipeline and recent launches.

Uncertain Long‑Term Scale of New Products

While Midevo’s early performance has been encouraging, management acknowledged that the ultimate size of the treated population and duration of therapy remain uncertain. The projected $500 million peak opportunity hinges on the success of the ACTION trial in first‑line use and on how long patients stay on treatment in routine practice.

Guidance and Outlook Emphasize Growth with Caution

Looking ahead, Jazz reaffirmed its 2026 non‑GAAP revenue guidance of $4.25 billion to $4.5 billion following the strong first quarter, which featured record revenue, EPS of $6.34 and robust cash flow. Management also reiterated expectations for second‑half headwinds in sleep, a decline in Xyrem and authorized generic revenues, slight margin pressure and reduced second‑line Zepzelca use, balancing optimism on oncology and new launches with a measured view of risks.

Jazz’s earnings call painted a picture of a company in transition from a sleep‑centric player to a more diversified biopharma with a rapidly growing oncology franchise. While competitive, legal and pricing uncertainties remain, record revenue, strong product momentum and a healthy balance sheet suggest Jazz is well positioned, and investors will be watching upcoming zanidatumab decisions and Midevo data to gauge how durable this growth story will be.